PREVENTION OF TYPE 2 DIABETES

TABLE 1

Baseline characteristics of women who returned for at least one follow-up visit after randomization to placebo or troglitazone

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Placebo group | | | Troglitazone group | | | | *P* |
| *n* | 122 | | | 114 | | | |  |
| Clinical characteristics |  | | |  | | | |  |
| Age (years) | 34.3 | | ± 6.5 | 34.9 | | | ± 6.6 | 0.52 |
| BMI (kg/m2) | 30.3 | | ± 5.3 | 30.6 | | | ± 6.1 | 0.63 |
| Waist-to-hip circumference ratio | 48% | | | 43% | | | | 0.41 |
| OGTT |  | | |  | | | |  |
| Fasting glucose (mg/dl) | 98.1 | | ± 9.1 | 98.7 | | ± 10.2 | | 0.64 |
| 2-h glucose | 154.0 | | ± 24.0 | 154.4 | | ± 27.0 | | 0.97 |
| Total glucose area (mg/dl x min x 10-3) | 18.7 | | ± 2.0 | 18.9 | | ± 2.0 | | 0.25 |
| Impaired glucose tolerance | 72% | | | 69% | | | | 0.66 |
| Fasting insulin (µU/ml) | 16.0 | | ± 7.5 | 17 | | ± 10.8 | | 0.82 |
| Total insulin area (µU/ml x min) | 10,209 | | ± 5536 | 9,902 | | ± 6543 | | 0.55 |
| IVGTT |  | | |  | | | |  |
| Fasting glucose (mg/dl) | 94.3 | ± 10.4 | | 94.8 | ± 10.2 | | | 0.71 |
| *Kg* (min-1 x 100) | 1.48 | ± 0.40 | | 1.42 | ± 0.39 | | | 0.23 |
| Fasting insulin (µU/ml) | 18.7 | ± 9.7 | | 16.6 | ± 9.5 | | | 0.05 |
| *Si* (min-1 per µU/ml x 10-4)# | 2.28 | ± 1.75 | | 2.64 | ± 1.70 | | | 0.05 |
| AIRg (µU/ml x min)\*\* | 569 | ± 527 | | 454 | ± 360 | | | 0.18 |
| Total insulin area (units/ml x min) | 10,686 | ± 5686 | | 9,273 | ± 5434 | | | 0.03 |
| DI (SI x AIRg) | 983 | ± 697 | | 976 | ± 717 | | | 0.99 |